Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00720798 · ClinicalTrials.gov registry record · Phase 3
An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,067
- Enrollment target
NCT00720798 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 2,067 participants.
The verdict
NCT00720798, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,067 participants
- Enrollment target
Study Summary
This single-arm study evaluated the long-term efficacy and safety of tocilizumab in participants who had completed treatment in the tocilizumab core studies (NCT00106522 \[Roche protocol WA18062\], NCT00106574 \[Roche protocol WA18063\], and NCT00109408 \[Roche protocol WA17824\]) of adults with rheumatoid arthritis. Participants received tocilizumab alone or in combination with standard anti-rheumatic treatment.
Interventions
- DRUG Tocilizumab
- DRUG Non-steroidal anti-inflammatory drugs
- DRUG Disease-modifying anti-rheumatic drugs
- DRUG Oral corticosteroids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,067 participants |
| Start Date | 2005-09 |
| Est. Completion | 2013-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00720798
The ClinicalTrials.gov registry entry for NCT00720798 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,067 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Tocilizumab is the first listed.
NCT00720798 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00720798 about?
NCT00720798 is a clinical study titled "An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies". This single-arm study evaluated the long-term efficacy and safety of tocilizumab in participants who had completed treatment in the tocilizumab core studies (NCT00106522 \[Roche protocol WA18062\], NCT00106574 \[Roche protocol WA18063\], and NCT00109408 \[Roche protocol WA17824\]) of adults with rhe...
What is the current status of trial NCT00720798?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,067 participants. The study started on 2005-09. Estimated completion is 2013-04.
What interventions are being tested in trial NCT00720798?
The interventions under investigation include: Tocilizumab (DRUG), Non-steroidal anti-inflammatory drugs (DRUG), Disease-modifying anti-rheumatic drugs (DRUG), Oral corticosteroids (DRUG).
Who is sponsoring clinical trial NCT00720798?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.